Investing.comDoubao · 实盘不做把握 7/10不做原因:无增量信息
北京时间·🕒 发布 20:04:33·⟳ 抓取 20:04:55 +22s·⚡ 决策 10-19 20:09:21 +4m26s·8.3 天前
Altimmune 宣布将在 2026年11月 AASLD 大会展示 pemvidutide 的 IMPACT MASH 数据
这是 Investing.com（聚合站）转述的公司新闻稿，内容是预告 11月5-9日 AASLD 的展示安排；其中所有关键疗效与安全性数据（48周 IMPACT 肝硬度/ELF/肝脂肪/ALT 下降、GI 安全性）均为 2025-12-19 已发布并在 2026-05-28 EASL 展示过的旧数据，唯一新增的是会议日程与一个临床前仓鼠酒精摄入数据。距真正催化剂两周以上，此刻不构成可交易的预期差。
📄 原文Investing.com↗ 原文
Altimmune to present pemvidutide liver disease data at AASLD
Oil prices dip as Trump waives Russia sanctions GAITHERSBURG, Md. - Altimmune Inc. (NASDAQ:ALT) will present clinical a…
不做 Altimmune Inc.（ALT.US）
无增量事实：本条为 11月5-9日 AASLD 会议日程预告，核心 48周 IMPACT MASH 数据已于 2025-12-19 公布、2026-05 EASL 展示，距真正催化两周，盘前无可交易预期差；待 AASLD 现场出现未披露新数据再独立研判。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Altimmune 仅预告 11月 AASLD 展示安排，核心 IMPACT 48周 MASH 数据为 2025年12月已公布、2026年5月 EASL 已展示的旧数据，无增量临床事实且距会议两周，当前无可交易 edge，回避。
消息传播链
- 聚合站转述公司新闻稿，预告 AASLD 展示安排，标注 AI 生成；非首发一手数据披露。
关键理由
- 无即时交易逻辑：本条为会议日程预告而非新数据披露，关键数据早已公开。
主要风险
- 若 AASLD 实际展示包含未披露的新亚组/活检数据，届时可能成为真正催化，但此刻无法据预告预判方向。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-19 · 影响 weakens
未发现 AASLD 将披露超出既有 IMPACT 数据的新顶线结果；唯一新增为临床前仓鼠酒精摄入数据，不足以驱动股价。
检索:Altimmune pemvidutide AASLD 2026 new data biopsy topline November 原文 ↗
先例如何影响了这次决策
对本次决策的影响:确认当前不给交易腿；建议待 AASLD 实际披露新数据时再独立研判。
方向:无对齐先例；本条为无新增事实的会议日程预告，不适用以数据披露类先例校准。
涨幅量级:无可校准的当次催化，真正可定价时点为 11月 AASLD 现场，届时应另行检索数据披露先例。
形态:不适用
工具执行结果 · 成功 2 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 13 ms
{"result": "search_processed_events:agent query=`aasld 2026 denver november pemvidutide impact mash presentation | altimmune alt pemvidutide liver stiffness elf fibrosis phase 2b data | altimmune pemvidutide aasld 2026 presentati`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agen - web_search 成功 doubao_search · 1,635 ms
豆包搜索结果（原始查询:Altimmune pemvidutide IMPACT 48-week MASH liver stiffness ELF results previously announced；API SearchType:web）
原文全文
展开原文 · 1,930 字
Oil prices dip as Trump waives Russia sanctions
GAITHERSBURG, Md. - Altimmune Inc. (NASDAQ:ALT) will present clinical and preclinical data on pemvidutide at the American Association for the Study of Liver Diseases meeting taking place November 5-9, 2026, in Denver, Colorado, according to a press release statement.
The company will present 48-week results from its IMPACT Phase 2b study in metabolic dysfunction-associated steatohepatitis (MASH). The data showed treatment with pemvidutide achieved concurrent reductions in two non-invasive markers of fibrosis, liver stiffness and ELF score, as well as liver fat and alanine aminotransferase compared to placebo.
Additional IMPACT data indicated gastrointestinal adverse events were mild to moderate, with no severe gastrointestinal treatment-emergent adverse events reported. Treatment discontinuations due to adverse events were lower with pemvidutide than placebo.
The company will also present preclinical data showing a reduction in mean alcohol intake with pemvidutide in a hamster model.
The IMPACT Phase 2b trial enrolled 212 participants with biopsy-confirmed MASH and fibrosis stages F2 or F3. Participants were randomized to receive weekly subcutaneous pemvidutide doses at either 1.2 mg, 1.8 mg or placebo for 48 weeks.
Pemvidutide is an investigational peptide with balanced 1:1 glucagon/GLP-1 dual receptor agonist activity in development for treatment of MASH, alcohol use disorder and alcohol-associated liver disease. The FDA granted Fast Track designations to pemvidutide for treatment of MASH and alcohol use disorder, as well as Breakthrough Therapy Designation for MASH.
The company initiated its PERFORMA Phase 3 trial in MASH in July 2026 and completed enrollment of the RESTORE Phase 2 trial in alcohol-associated liver disease in August 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
GAITHERSBURG, Md. - Altimmune Inc. (NASDAQ:ALT) will present clinical and preclinical data on pemvidutide at the American Association for the Study of Liver Diseases meeting taking place November 5-9, 2026, in Denver, Colorado, according to a press release statement.
The company will present 48-week results from its IMPACT Phase 2b study in metabolic dysfunction-associated steatohepatitis (MASH). The data showed treatment with pemvidutide achieved concurrent reductions in two non-invasive markers of fibrosis, liver stiffness and ELF score, as well as liver fat and alanine aminotransferase compared to placebo.
Additional IMPACT data indicated gastrointestinal adverse events were mild to moderate, with no severe gastrointestinal treatment-emergent adverse events reported. Treatment discontinuations due to adverse events were lower with pemvidutide than placebo.
The company will also present preclinical data showing a reduction in mean alcohol intake with pemvidutide in a hamster model.
The IMPACT Phase 2b trial enrolled 212 participants with biopsy-confirmed MASH and fibrosis stages F2 or F3. Participants were randomized to receive weekly subcutaneous pemvidutide doses at either 1.2 mg, 1.8 mg or placebo for 48 weeks.
Pemvidutide is an investigational peptide with balanced 1:1 glucagon/GLP-1 dual receptor agonist activity in development for treatment of MASH, alcohol use disorder and alcohol-associated liver disease. The FDA granted Fast Track designations to pemvidutide for treatment of MASH and alcohol use disorder, as well as Breakthrough Therapy Designation for MASH.
The company initiated its PERFORMA Phase 3 trial in MASH in July 2026 and completed enrollment of the RESTORE Phase 2 trial in alcohol-associated liver disease in August 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
0d51edd3c9· 2026-10-19 20:09 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前